213 related articles for article (PubMed ID: 34741547)
21. Verification of musculoskeletal FDG-PET-CT findings performed for melanoma staging.
Mansour AA; Kelley MC; Hatmaker AR; Holt GE; Schwartz HS
Ann Surg Oncol; 2010 Apr; 17(4):1144-51. PubMed ID: 19967460
[TBL] [Abstract][Full Text] [Related]
22. Performance of whole-body
Ozturk K; Gencturk M; Caicedo-Granados E; Li F; Cayci Z
Eur Arch Otorhinolaryngol; 2019 Mar; 276(3):847-855. PubMed ID: 30604061
[TBL] [Abstract][Full Text] [Related]
23. Whole-body
Gajjala SR; Hulikal N; Kadiyala S; Kottu R; Kalawat T
Indian J Med Res; 2018 Mar; 147(3):256-262. PubMed ID: 29923514
[TBL] [Abstract][Full Text] [Related]
24. Diagnostic value of integrated ¹⁸F-fluoro-2-deoxyglucose positron emission tomography/computed tomography in recurrent epithelial ovarian cancer: accuracy of patient selection for secondary cytoreduction in 134 patients.
Lee YJ; Kim YM; Jung PS; Lee JJ; Kim JK; Kim YT; Nam JH
J Gynecol Oncol; 2018 May; 29(3):e36. PubMed ID: 29400023
[TBL] [Abstract][Full Text] [Related]
25. Clinical applications of fluorodeoxyglucose--positron emission tomography in the management of malignant melanoma.
Kumar R; Alavi A
Curr Opin Oncol; 2005 Mar; 17(2):154-9. PubMed ID: 15725921
[TBL] [Abstract][Full Text] [Related]
26. S-100B as an extra selection tool for FDG PET/CT scanning in follow-up of AJCC stage III melanoma patients.
Deckers EA; Wevers KP; Muller Kobold AC; Damude S; Vrielink OM; van Ginkel RJ; Been LB; van Leeuwen BL; Hoekstra HJ; Kruijff S
J Surg Oncol; 2019 Nov; 120(6):1031-1037. PubMed ID: 31468535
[TBL] [Abstract][Full Text] [Related]
27. Restaging [
Mahajan S; Barker CA; Mauguen A; Singh B; Pandit-Taskar N
J Am Acad Dermatol; 2020 Apr; 82(4):878-886. PubMed ID: 31562942
[TBL] [Abstract][Full Text] [Related]
28. Evaluation of high-risk melanoma: comparison of [18F]FDG PET and high-dose 67Ga SPET.
Kalff V; Hicks RJ; Ware RE; Greer B; Binns DS; Hogg A
Eur J Nucl Med Mol Imaging; 2002 Apr; 29(4):506-15. PubMed ID: 11914889
[TBL] [Abstract][Full Text] [Related]
29. Role of 18F-Fluorodeoxyglucose Positron Emission Tomography or Positron Emission Tomography/Computed Tomography for the Detection of Recurrent Disease after Treatment of Malignant Melanoma.
Lee JW; Nam SB; Kim SJ
Oncology; 2019; 97(5):286-293. PubMed ID: 31437839
[TBL] [Abstract][Full Text] [Related]
30. Association of Fludeoxyglucose F 18-Labeled Positron Emission Tomography and Computed Tomography With the Detection of Oropharyngeal Cancer Recurrence.
Sivarajah S; Isaac A; Cooper T; Zhang H; Puttagunta L; Abele J; Biron V; Harris J; Seikaly H; O' Connell DA
JAMA Otolaryngol Head Neck Surg; 2018 Nov; 144(11):1037-1043. PubMed ID: 30242338
[TBL] [Abstract][Full Text] [Related]
31. Findings of computed tomography in stage IIB and IIC melanoma: a six-year retrospective study in the South-East of Scotland.
Orfaniotis G; Mennie JC; Fairbairn N; Butterworth M
J Plast Reconstr Aesthet Surg; 2012 Sep; 65(9):1216-9. PubMed ID: 22525255
[TBL] [Abstract][Full Text] [Related]
32. Role of
Piccardo A; Trimboli P; Puntoni M; Foppiani L; Treglia G; Naseri M; Bottoni GL; Massollo M; Sola S; Ferrarazzo G; Bruzzone M; Catrambone U; Arlandini A; Paone G; Ceriani L; Cabria M; Giovanella L
Thyroid; 2019 Apr; 29(4):549-556. PubMed ID: 30864903
[TBL] [Abstract][Full Text] [Related]
33. Use of Diffusion-Weighted Imaging and
Noij DP; Martens RM; Koopman T; Hoekstra OS; Comans EFI; Zwezerijnen B; de Bree R; de Graaf P; Castelijns JA
Clin Oncol (R Coll Radiol); 2018 Dec; 30(12):780-792. PubMed ID: 30318343
[TBL] [Abstract][Full Text] [Related]
34. Surveillance imaging with FDG-PET/CT in the post-operative follow-up of stage 3 melanoma.
Lewin J; Sayers L; Kee D; Walpole I; Sanelli A; Te Marvelde L; Herschtal A; Spillane J; Gyorki D; Speakman D; Estall V; Donahoe S; Pohl M; Pope K; Chua M; Sandhu S; McArthur GA; McCormack CJ; Henderson M; Hicks RJ; Shackleton M
Ann Oncol; 2018 Jul; 29(7):1569-1574. PubMed ID: 29659679
[TBL] [Abstract][Full Text] [Related]
35. Diagnostic accuracy of (18)F-FDG-PET/CT in early and late stages of high-risk cutaneous malignant melanoma.
Gellén E; Sántha O; Janka E; Juhász I; Péter Z; Erdei I; Lukács R; Fedinecz N; Galuska L; Remenyik É; Emri G
J Eur Acad Dermatol Venereol; 2015 Oct; 29(10):1938-44. PubMed ID: 25753249
[TBL] [Abstract][Full Text] [Related]
36. FDG PET in early stage cutaneous malignant melanoma.
McIvor J; Siew T; Campbell A; McCarthy M
J Med Imaging Radiat Oncol; 2014 Apr; 58(2):149-54; quiz 266. PubMed ID: 24690243
[TBL] [Abstract][Full Text] [Related]
37. A multicenter prospective evaluation of the clinical utility of F-18 FDG-PET/CT in patients with AJCC stage IIIB or IIIC extremity melanoma.
Beasley GM; Parsons C; Broadwater G; Selim MA; Marzban S; Abernethy AP; Salama AK; Eikman EA; Wong T; Zager JS; Tyler DS
Ann Surg; 2012 Aug; 256(2):350-6. PubMed ID: 22691370
[TBL] [Abstract][Full Text] [Related]
38. No benefit in staging fluorodeoxyglucose-positron emission tomography in clinically node-negative head and neck cutaneous melanoma.
Bikhchandani J; Wood J; Richards AT; Smith RB
Head Neck; 2014 Sep; 36(9):1313-6. PubMed ID: 23956077
[TBL] [Abstract][Full Text] [Related]
39. Clinical role of 18F-fluorodeoxyglucose positron emission tomography/computed tomography in post-operative follow up of gastric cancer: initial results.
Sun L; Su XH; Guan YS; Pan WM; Luo ZM; Wei JH; Wu H
World J Gastroenterol; 2008 Aug; 14(29):4627-32. PubMed ID: 18698676
[TBL] [Abstract][Full Text] [Related]
40. Prognostic implication of fluorine-18 fluorodeoxyglucose positron emission tomography/computed tomography in patients with recurrent papillary thyroid cancer.
Kang JH; Jung DW; Pak KJ; Kim IJ; Kim HJ; Cho JK; Shin SC; Wang SG; Lee BJ
Head Neck; 2018 Jan; 40(1):94-102. PubMed ID: 29130586
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
